Hainan Huluwa Pharmaceutical Group Stock Forum

The company's high P/E ratio amid shrinking medium-term earnings is worrisome. The market's expected 42% growth next year highlights the company's recent earnings decline. The share price may drop further if business prospects don't significantly improve.

Despite a high rate of reinvestment, the low ROE suggests that this reinvestment is not benefiting its investors and is negatively impacting earnings growth. Caution is advised when dealing with this company.